the excellent in-vitro activities of the newer beta-lactam agents ( ceftriaxone , cefotaxime and , particularly , imipenem ) and vancomycin against penicillin-resistant pneumococci offer a considerable promise for their use in the treatment of pneumococcal meningitis caused by these strains .
C0007561
ceftriaxone
C0007554
cefotaxime